Stockreport

ImmunityBio's allogeneic CD19 cell therapy shows complete response beyond 15 months [Yahoo! Finance]

ImmunityBio, Inc.  (IBRX) 
PDF months of complete response in patients with Waldenström Non-Hodgkins lymphoma, a rare B-cell malignancy. In the ongoing Phase I QUILT-106 study (NCT06334991), CAR-NK, [Read more]